MGMT and glioblastoma: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been identified as a predictive marker for GBM patients treated with temozolomide (TMZ) chemotherapy, and Higher level of MGMT promoter unmethylation lead to TMZ resistance [36].